AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein). It is being developed by Acologix,...
- Mechanism
- Curator reviewed
In several preclinical models, AC-100 has demonstrated potent and selective dental tissue and bone formation activity, however the exact mechanism is not known. One study (PMID:15153459) showed that AC-100 enhances dental pulp stem cell (DPSC) proliferation by down-regulating P16, accompanied by up-regulation of ubiquitin protein ligase E3A and human ubiquitin-related protein SUMO-1. Enhanced cell proliferation required intact RGD and SGDG motifs in the peptide. This study shows that AC-100 can promote DPSC proliferation, with a potential role in pulp repair.
- Primary indication
- Investigated for use/treatment in periodontal disease.Curator reviewed
- Code names
- AC-100
Resolves to
What you can answer from here — as of April 08, 2025
Which companies are running trials of AC-100, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account